How it works
Proposed to induce telomerase reverse transcriptase expression, allowing telomere elongation in somatic cells, and to normalise melatonin rhythm through pineal action.
Structure: Tetrapeptide (Ala-Glu-Asp-Gly)
Reported benefits
- Telomere lengthening reported in cell culture
- Improved sleep–wake rhythm
- Longevity signals in long-running Russian cohort studies
Practical considerations
- Key studies are decades old and largely unreplicated in the West
- Telomerase activation carries a theoretical oncogenic concern
- Usually run as short cycles two or three times per year
Side effects and risks
- Sparse safety data
- Occasional drowsiness
- Injection-site reaction
Epitalon dosing overview
5–10 mg daily for 10–20 days, cycled 1–3 times per year
| Context | Amount | Frequency | Route |
|---|---|---|---|
| Commonly cited course | 5–10 mg | Daily for 10–20 days | Subcutaneous |
| Repeat frequency | — | 1–3 courses per year | — |
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Epitalon FAQ
Does epitalon lengthen telomeres?
Cell-culture work reported telomerase activation in human fibroblasts. Whether that translates to telomere lengthening or any clinical benefit in people has not been demonstrated in controlled trials.
Why is it dosed in short courses?
The Russian research tradition it comes from used pulsed courses on the premise that effects are mediated by gene expression rather than sustained plasma levels.
Is the longevity data reliable?
The frequently cited human mortality figures come from older Russian studies with methodology that would not meet current trial standards. Treat them as hypothesis-generating, not proof.
Research references
- Khavinson et al., 2003 — Epithalon and telomerase activity in human somatic cells